BioSpace News Archive

BioMidwest

AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)

Two analyses of the Phase 3 CLL14 study evaluated minimal residual disease (MRD) measurements for previously untreated CLL patients taking VENCLEXTA/VENCLYXTO in combination with obinutuzumab

December 5, 2020
·
17 min read
Biotech Beach

Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020

83% Overall Response Rate in Most Recent Evaluable Cohort of Heavily Pre-Treated Multiple Myeloma Patients

December 5, 2020
·
13 min read
Drug Development

ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

Updated Data Demonstrating Favorable Safety Profile and Encouraging Monotherapy Activity in BPDCN Presented During Oral Session

December 5, 2020
·
8 min read
Drug Development

Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies

December 5, 2020
·
5 min read
Drug Development

Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 2 Zella 201 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Acute Myeloid Leukemia at 62nd ASH Annual Meeting

Additional Presentations Provide Updates on Development Programs for Investigational Agents TP-3654 and Dubermatinib

December 5, 2020
·
9 min read
Biotech Beach

New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial

Unparalleled 44 Percent Estimated Four-Year Overall Survival Rate Among Refractory Large B-cell Lymphoma Patients After a Single Infusion of Yescarta

December 5, 2020
·
11 min read
Pharm Country

Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas

Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%

December 5, 2020
·
17 min read
Drug Development

Preclinical Data Demonstrate Anti-Viral Activity of AlloVir’s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy

Data presented in an oral presentation at the 62nd American Society of Hematology Annual Meeting

December 5, 2020
·
5 min read
Biotech Beach

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting

Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a SETD2/RUNX1 mutation

December 5, 2020
·
9 min read
Drug Development

Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML

61% Composite CR Rate in RARA-Positive Newly Diagnosed Unfit AML Patients, with Median Overall Survival of 18 Months Among Responders

December 5, 2020
·
10 min read